UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of February 2024

Commission File Number: 001-38097

ARGENX SE
(Translation of registrant's name into English)

Laarderhoogtweg 25
1101 EB Amsterdam, the Netherlands
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

EXPLANATORY NOTE

On February 29, 2024, argenx SE (the "Company") issued a press release, an investor presentation and its full year 2023 financial results, copies of which are attached hereto as Exhibits 99.1, 99.2 and 99.3, respectively, and are incorporated by reference herein.

The information contained in this Current Report on Form 6-K, including Exhibit 99.1, Exhibit 99.2 and Exhibit 99.3, shall be deemed to be incorporated by reference into the Company's Registration Statements on Forms F-3 (File No. 333-258251) and S-8 (File Nos. 333-225375, 333-258253, and 333-274721), and to be part thereof from the date on which this Current Report on Form 6-K is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

Exhibit	Description
99.1	Press Release dated February 29, 2024
99.2	Investor Presentation
99.3	Full Year 2023 Financial Results

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ARGENX SE

Date: February 29, 2024

By: /s/ Hemamalini (Malini) Moorthy
Name: Hemamalini (Malini) Moorthy
Title: General Counsel

argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update

$374 million in fourth quarter and $1.2 billion in full year global net product sales

sBLA for VYVGART® Hytrulo for CIDP accepted for priority review by FDA with PDUFA target action date of June 21, 2024

On track to report data from six Phase 2 proof-of-concept trials by end of 2024

Management to host conference call today at 2:30 pm CET (8:30 am ET)

February 29, 2024, 7:00 am CET

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today reported financial results for the full year 2023 and provided a fourth quarter business update.

"argenx reached thousands of new patients and their families in 2023 by delivering on our commitment to make VYVGART available to the global MG community," said Tim Van Hauwermeiren, Chief Executive Officer of argenx. "This expansion demonstrates that VYVGART has the potential to address the high unmet need for innovation in patients suffering from MG, and moves us closer to sustainability as we build an integrated immunology company. Clinically, we generated significant data through multiple study readouts, achieving key milestones for both the CIDP and MMN patient communities and importantly advancing our second molecule, empasiprubart. Looking forward to 2024, we will act with a continued sense of purpose to expand our patient reach. We will use the learnings and momentum from our gMG launch to strategically lay the groundwork for a potential CIDP approval, leveraging our current infrastructure and deep relationships in the neurology community to position VYVGART SC for success. CIDP patients have been waiting for innovation, and we are eager to translate the transformative ADHERE data into potential benefit for patients as quickly as possible."

FOURTH QUARTER 2023 AND RECENT BUSINESS UPDATE

Reaching More Patients with VYVGART

VYVGART® (efgartigimod alfa-fcab) is a first-in-class antibody fragment targeting the neonatal Fc receptor (FcRn), and is now approved in more than 30 countries globally for the treatment of generalized myasthenia gravis (gMG). VYVGART subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) is approved in the U.S. (as VYVGART Hytrulo), Japan (as VYVDURA®) and Europe, making VYVGART the only gMG treatment available as both an IV and simple SC injection. argenx is planning to reach more patients commercially through its multi-dimensional expansion efforts, including patients earlier in the MG treatment paradigm and new patient populations through global regulatory approvals for MG and the expansion of use to treat additional autoimmune indications.

- Generated global net product revenues (inclusive of both VYVGART and VYVGART SC) of $374 million in the fourth quarter and $1.2 billion in the full year of 2023
- Medicines and Healthcare products Regulatory Agency (MHRA) approved VYVGART SC in the United Kingdom for the treatment of adult patients with gMG on February 6, 2024, with self-administration
- Ministry of Health, Labour and Welfare (MHLW) approved VYVDURA in Japan for the treatment of adult patients with gMG, inclusive of seronegative patients, on January 18, 2024, with self-administration
- Decisions on regulatory approvals of VYVGART for gMG expected in Switzerland, Australia, Saudi Arabia and South Korea by end of 2024
- Decision on approval of VYVGART SC for gMG in China through Zai Lab expected by end of 2024
- Decision on approval of VYVGART for primary immune thrombocytopenia (ITP) in Japan expected in first quarter of 2024
- Supplemental Biologics License Application (sBLA) for VYVGART Hytrulo accepted for priority review by FDA for chronic inflammatory demyelinating polyneuropathy (CIDP); Prescription Drug User Fee Act (PDUFA) target action date of June 21, 2024
- Regulatory submissions of VYVGART SC for CIDP in Japan, Europe, China and Canada expected in 2024
- Registrational studies to expand VYVGART label into broader MG populations, including in seronegative patients, expected to start in 2024
- Update on pre-filled syringe development expected in first half of 2024; ongoing clinical studies expected to support potential approval in gMG and CIDP in 2024

Advancing Current Pipeline

argenx continues to demonstrate breadth and depth within its immunology pipeline and is advancing multiple pipeline-in-a-product candidates. With efgartigimod, argenx is solidifying its leadership in FcRn and is on track to be approved or in development in 15 autoimmune indications by 2025. Beyond efgartigimod, argenx is advancing its earlier stage pipeline programs, including empasiprubart (C2 inhibitor) with Phase 2 studies ongoing in multifocal motor neuropathy (MMN), delayed graft function (DGF) and dermatomyositis (DM). In addition, argenx is evaluating ARGX-119, a muscle-specific kinase (MuSK) agonist in both congenital myasthenic syndrome (CMS) and amyotrophic lateral sclerosis (ALS).

- Evaluation ongoing to determine path forward in BALLAD study evaluating efgartigimod in bullous pemphigoid (BP), with an update expected in 2024
- Topline data from Phase 2 RHO study evaluating efgartigimod in primary Sjogren's syndrome expected in first half of 2024
- Topline data from Phase 2 ALPHA study evaluating efgartigimod in post-COVID-19 postural orthostatic tachycardia syndrome (PC-POTS) expected in first half of 2024

- Topline data from seamless Phase 2/3 ALKIVIA study evaluating efgartigimod across three myositis subsets (immune-mediated necrotizing myopathy (IMNM), anti-synthetase syndrome (ASyS), and DM) expected in second half of 2024
- Full Phase 2 topline data from ARDA study evaluating empasiprubart in MMN expected to be shared in 2024; cohort 2 is ongoing to determine dose response ahead of Phase 3 study start
- Phase 1 study of ARGX-119 ongoing in healthy volunteers; subsequent Phase 1b/2a trials planned to assess early signal detection in patients with CMS and ALS in 2024

Leveraging Repeatable Innovation Playbook to Drive Long-Term Pipeline Growth

argenx continues to invest in its discovery engine, the Immunology Innovation Program (IIP), to drive long-term sustainable pipeline growth. Through the IIP, four new pipeline candidates have been nominated, including: ARGX-213 targeting FcRn and further solidifying argenx's leadership in this new class of medicine; ARGX-121 and ARGX-220, which are first-in-class targets broadening argenx's focus across the immune system; and ARGX-109, targeting IL-6, which plays an important role in inflammation.

- On track to file four investigational new drug (IND) applications by end of 2025
- Received $30M milestone from AbbVie for advancement of ABBV-151 (ARGX-115) to Phase 2

FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS

argenx SE

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS

	Three Months Ended December 31,		Twelve Months Ended December 31,	
(in thousands of $ except for shares and EPS)	**2023**	**2022**	**2023**	**2022**
Product net sales	$ 374,351	$ 173,396	$ 1,190,783	$ 400,720
Collaboration revenue	32,486	764	35,533	10,026
Other operating income	11,003	7,956	42,278	34,520
Total operating income	**$ 417,840**	**$ 182,116**	**$ 1,268,594**	**$ 445,267**
Cost of sales	$ (39,477)	$ (12,786)	$ (117,835)	$ (29,431)
Research and development expenses	(306,373)	(147,798)	(859,492)	(663,366)
Selling, general and administrative expenses	(208,826)	(135,287)	(711,905)	(472,132)
Loss from investment in joint venture	(1,788)	(677)	(4,411)	(677)
Total operating expenses	**(556,464)**	**(296,548)**	**(1,693,643)**	**(1,165,607)**
Operating loss	**$ (138,624)**	**$ (114,432)**	**$ (425,049)**	**$ (720,341)**
Financial income	$ 40,308	$ 13,925	$ 107,386	$ 27,665
Financial expense	(280)	(990)	(906)	(3,906)
Exchange gains/(losses)	37,418	60,259	14,073	(32,732)
Loss for the period before taxes	**$ (61,178)**	**$ (41,238)**	**$ (304,496)**	**$ (729,314)**
Income tax benefit / (expense)	$ (37,994)	$ 2,625	$ 9,443	$ 19,720
Loss for the period	**$ (99,172)**	**$ (38,613)**	**$ (295,053)**	**$ (709,594)**
Loss for the year attributable to:				
Owners of the parent	$ (99,172)	$ (38,613)	$ (295,053)	$ (709,594)
Weighted average number of shares outstanding	59,118,827	55,364,124	57,169,253	54,381,371
Basis and diluted (loss) per share (in $)	(1.68)	(0.70)	(5.16)	(13.05)
Net increase/(decrease) in cash, cash equivalents and current financial assets compared to year-end 2022 and 2021			$ 987,296	$ (144,180)
Cash and cash equivalents and current financial assets at the end of the period			$ 3,179,844	$ 2,192,548

DETAILS OF THE FINANCIAL RESULTS

Total operating income for the fourth quarter and full year in 2023 was $418 million and $1,269 million, respectively, compared to $182 million and $445 million for the same periods in 2022, and mainly consists of:

- **Product net sales** of VYVGART and VYVGART SC for the fourth quarter and full year in 2023, were $374 million and $1,191 million, respectively, compared to $173 million and $401 million for the same periods in 2022.
- **Collaboration revenue** for the fourth quarter and full year in 2023 was $32 million and $36 million, respectively, compared to $1 million and $10 million for the same periods in 2022. The increase is mainly related to the clinical development milestone argenx achieved with AbbVie following the dosing of the first patient in the Phase 2 trial for ABBV-151. Collaboration revenue for full year in 2023 also includes $1 million in royalty revenue from VYVGART sales in China.
- **Other operating income** for the fourth quarter and full year in 2023 was $11 million and $42 million, respectively, compared to $8 million and $35 million for the same periods in 2022. The other operating income for the fourth quarter and full year in 2023, primarily relates to research and development tax incentives and payroll tax rebates.

Total operating expenses for the fourth quarter and full year in 2023 were $556 million and $1,694 million, respectively, compared to $297 million and $1,166 million for the same periods in 2022, and mainly consists of:

- **Cost of sales** for the fourth quarter and full year in 2023 was $39 million and $118 million, respectively, compared to $13 million and $29 million for the same periods in 2022. The cost of sales was recognized with respect to the sale of VYVGART and VYVGART SC.
- **Research and development expenses** for the fourth quarter and full year in 2023 were $306 million and $859 million, respectively, compared to $148 million and $663 million for the same periods in 2022. The research and development expenses mainly relate to external research and development expenses and personnel expenses incurred in the clinical development of efgartigimod in various indications and the expansion of other clinical and preclinical pipeline candidates. The research and development expenses for the fourth quarter and the full year in 2023, includes the amortization of the priority review voucher submitted with the sBLA filling for VYVGART Hytrulo for the treatment of CIDP, which resulted in an expense of $102 million.

- **Selling, general and administrative expenses** for the fourth quarter and full year in 2023 were $209 million and $712 million, respectively, compared to $135 million and $472 million for the same periods in 2022. The selling, general and administrative expenses mainly relate to professional and marketing fees linked to the commercialization of VYVGART and VYVGART SC, and personnel expenses.

Financial income for the fourth quarter and full year in 2023 was $40 million and $107 million, respectively, compared to $14 million and $28 million for the same periods in 2022. The increase in financial income is mainly due to an increase in interest income which results from higher interest rates and a higher amount of current financial assets, cash and cash equivalents as a result of the financing round in July 2023.

Exchange gains for the fourth quarter and full year in 2023 were $37 million and $14 million respectively, compared to $60 million of exchange gains and $33 million of exchange losses for the same periods in 2022. Exchange gains/losses are mainly attributable to unrealized exchange rate gains or losses on the cash, cash equivalents and current financial assets denominated in Euro.

Income tax for the fourth quarter and full year in 2023 was $38 million of tax expense and $9 million of tax benefit, respectively, compared to $3 million and $20 million of tax benefit for the same periods in 2022. Tax expense for the fourth quarter in 2023, consists of $12 million of income tax benefit and $50 million of deferred tax expense, compared to $12 million of income tax expense and $15 million of deferred tax benefit for the comparable prior period.

Net loss for the fourth quarter and full year in 2023, was $99 million and $295 million, respectively, compared to $39 million and $710 million over the prior year periods. On a per weighted average share basis, the net loss was $5.16 and $13.05 for the twelve months ended December 31, 2023 and 2022, respectively.

Cash, cash equivalents and current financial assets totalled $3.2 billion as of December 31, 2023, compared to $2.2 billion as of December 31, 2022. The increase in cash and cash equivalents and current financial assets resulted primarily from the closing of a global offering of shares, including a U.S. offering, which resulted in the receipt of $1.2 billion in net proceeds in July 2023, partially offset by net cash flows used in operating activities.

FINANCIAL GUIDANCE

Based on its current operating plans, argenx expects its combined Research and development and Selling, general and administrative expenses in 2024 to be less than $2 billion. argenx expects to utilize up to $500 million of net cash in 2024 on these anticipated operating expenses as well as working capital and capital expenditures.

EXPECTED 2024 FINANCIAL CALENDAR

- May 9, 2024: Q1 2024 financial results and business update
- July 25, 2024: Q2 2024 financial results and business update
- October 31, 2024: Q3 2024 financial results and business update

CONFERENCE CALL DETAILS
The full year 2023 financial results and fourth quarter business update will be discussed during a conference call and webcast presentation today at 2:30 pm CET/8:30 am ET. A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website.

Dial-in numbers:
Please dial in 15 minutes prior to the live call.

Belgium	32 800 50 201
France	33 800 943355
Netherlands	31 20 795 1090
United Kingdom	44 800 358 0970
United States	1 888 415 4250
Japan	81 3 4578 9081
Switzerland	41 43 210 11 32

About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker, globally in the U.S., Japan, Israel, the EU, the UK, China and Canada. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Twitter, and Instagram.

For further information, please contact:

Media:
Ben Petok
bpetok@argenx.com

Investors:
Alexandra Roy (US)
aroy@argenx.com

Lynn Elton (EU)
lelton@argenx.com

Forward-looking Statements

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements." These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "plans," "aims," "continues," "anticipates," "expects," "will," or "commitment" and include statements argenx makes concerning its utilization of its learnings and momentum from its gMG launch for a potential CIDP approval and to position VYVGART SC for success; its plans to expand its patient reach, including through its multidimensional expansion efforts aimed at including patients earlier in the MG treatment paradigm and pursuing global regulatory approvals for MG as well as additional autoimmune indications; our goal to translate the ADHERE data into potential benefit for patients; the advancement of, and anticipated clinical development, data readouts and regulatory milestones and plans, including: (1) expected decisions on regulatory approvals of VYVGART for gMG in Switzerland, Australia, Saudi Arabia and South Korea by end of 2024, (2) expected decisions on approval of VYVGART SC for gMG in China through Zai Lab by end of 2024, (3) expected decisions on approval of VYVGART for ITP in Japan in the first quarter of 2024, (4) expected regulatory submissions of VYVGART SC of CIDP in Japan, Europe, China and Canada in 2024, (5) the expansion of our VYVGART registrational studies into broader MG populations, including in seronegative patients, expected to start in 2024, (6) the update on pre-filled syringe development expected in the first half of 2024, (7) clinical studies expected to support potential approval in gMG and CIDP in 2024, (8) expected update on the path forward for BALLAD study in 2024, (9) expected topline data from Phase 2 RHO in the first half of 2024, (10) expected topline data from Phase 2 ALPHA study in the first half of 2024, (11) expected topline data from Phase 2/3 ALKIVIA in the second half of 2024, (12) the full Phase 2 topline data from ARDA study expected in 2024, (13) planned Phase 1b/2a clinical trials of ARGX-119 in 2024, (14) four IND applications expected to be filed by end of 2025, (15) expected data from six Phase 2 proof-of-concept trials by the end of 2024, and (16) the expected approval or development in 15 autoimmune indications by 2025; the potential of its continued investment in its IIP to drive long-term sustainable pipeline growth; its future financial and operating performance, including its anticipated operating expenses and utilization of net cash for 2024; and our goal of translating immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx's actual results may differ materially from those predicted by the forward-looking statements as a result of various important factors, including but not limited to, the results of argenx's clinical trials, expectations regarding the inherent uncertainties associated with development of novel drug therapies, preclinical and clinical trial and product development activities and regulatory approval requirements, the acceptance of our products and product candidates by our patients as safe, effective and cost-effective, and the impact of governmental laws and regulations on our business. A further list and description of these risks, uncertainties and other risks can be found in argenx's U.S. Securities and Exchange Commission (SEC) filings and reports, including in argenx's most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by law.


argenx
FY/4Q 2023 EARNINGS CALL | FEBRUARY 29, 2024
Reaching Patients through Immunology Innovation

Forward Looking Statements

- This presentation has been prepared by argenx se ("argenx" or the "company") for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or the company or any director, employee, agent, or adviser of the company. This presentation does not purport to be all-inclusive or to contain all of the information you may desire. Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the company's own internal estimates and research. While argenx believes these third-party studies, publications, surveys and other data to be reliab as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third party sources. In addition, no independent source has evaluated the reasonableness or accuracy of argenx's internal estimates or research and no reliance should be made on any information or statements made in this presentation relating to or based on such internal estimates and research.

- Certain statements contained in this presentation, other than present and historical facts and conditions independently verifiable at the date hereof, may constitute forward-looking statements. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "plans," "aims," "continues," "anticipates," "expects," "will," or "commitment" and include statements argenx makes concerning its Immunology Innovation Program and its pipeline, including argenx's goal to expand technical capabilities through collaborati with different partners to drive internal and external value creation; the expected approval or development in 15 autoimmune indications by 2025; our plans to maximize the VYVGART opportur by its launch strategy success and expanding opportunities for MG; the advancement of, and anticipated clinical development, data readouts and regulatory milestones and plans, including: (1) t update on pre-filled syringe ("PFS") development, (2) expected decisions on approval of VYVGART for ITP in Japan in the first quarter of 2024, (3) expected PoC study readouts in 2024 and beyor (5) expected regulatory submissions of VYVGART SC of CIDP in 2024, (6) the Full Phase 2 MMN data expected in 2024, (7) the planned Phase 1b/2a clinical trials of ARGX-119 in 2024; its plans to expand its patient reach, including through its multidimensional expansion efforts aimed at expanding opportunities for MG and pursuing global regulatory approvals for MG; its goal to continue drive transformational outcomes for patients and maximize value creation and patient impact by reaching new gMG patients with VYVGART and leveraging MG know-how into future indications its future financial and operating performance, including its anticipated operating expenses and cash burn for 2024; its autoimmune market opportunities; its goal to address the unseen sufferin in CIDP; and its commitment to value creation. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements a not guarantees of future performance. argenx's actual results may differ materially from those predicted by the forward-looking statements as a result of various important factors, including but not limited to, the results of argenx's clinical trials, expectations regarding the inherent uncertainties associated with development of novel drug therapies, preclinical and clinical trial and produ development activities and regulatory approval requirements, the acceptance of our products and product candidates by our patients as safe, effective and cost-effective, and the impact of governmental laws and regulations on our business. A further list and description of these risks, uncertainties and other risks can be found in argenx's U.S. Securities and Exchange Commission (SEC) filings and reports, including in argenx's most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. argenx undertakes no obligation to publicly update or revise the information in this presentation, including any forward-looking statements, except as may be required by law.

- This presentation contains trademarks, trade names and service marks of other companies, which are the property of their respective owners.


Our Innovation Horizons
Immunology Innovation Program
ARGX-109
(Anti-IL-6)
ARGX-213
(Anti-FcRn)
ARGX-121
ARGX-220
Pipeline
Empasiprubart
POC established in MMN
Trials in DGF and DM
ARGX-119
Phase 1b/2a trials in
CMS and ALS
VYVGART Opportunity
VYVGART®
(efgartigimod alfa-fcab)
Injection for Intravenous Use
400 mg/20 mL vial
VYVGART® Hytrulo
(efgartigimod alfa and
hyaluronidase-qvfc)
Subcutaneous Injection
180 mg/mL and 2000 U/mL vial
$1.2B in gMG revenue in 202
CIDP sBLA accepted
PDUFA June 21, 2024
ITP MAA filed
15 indications
in development by 202
PFS in development

Maximizing the VYVGART Opportunity



Launch Strategy Success



Expanding MG Opportunity

ITP

March 2024 decision
Japan (VYVGART IV)

CIDP

PDUFA June 21, 2024
US (VYVGART SC)

Upcoming Regulatory Decisions

argenx


This is
Just the
Beginning
Expected 2024 PoC study readouts
Beyond 2024 PoC studies
TED
100K
Sjogren's
330K
PC-POTS
500K
IMNM
6K
BP
52K
LN
40K
MN
80K
AAV
105K
AMR
8K
#14
ASyS
11K
DM
70K
Myasthenia Gravis
Launched
2022
65K
Chronic Inflammatory Demyelinating Polyneuropathy
FDA PDUFA
June 21, 2024
24K
ITP
Japan Regulatory Decision
Q1 2024
17K
Phase 2 Proof of Concept
Potential 2024 Phase 3 Sta
2024 Phase 3 Start
*** argenx market research; US prevalence numbers (except Japan ITP)

Empasiprubart
Targeting Complement Upstream



Full Phase 2 MMN data expected in 2024

Sweeping antibody targeting C2

91% reduction in need for IVIg rescue with empasiprubart in cohort 1

ARGX-119
Enhancing the NMJ



Ph1b/2a in CMS and ALS to start in 2024

First-in-class MuSK agonist

Phase 1 study supports advancement into PoC studies

Natural history studies ongoing in both MMN and CMS to better understand real-world experience of patients

argenx

Pipeline Growth Driven By Immunology Innovation Program

Fourth Quarter 2023 Revenue

Product Net Sales: 2023 Full Year with $1,191 million and Q4 2023 with $374 million



Product Net Sales by Region

(in millions of $)	Q4 2023	Q3 2023	QoQ % Growth
US	326	280	16%
Japan	17	15	15%
EMEA	24	26	-9%
China	7	7	0%
Total	**374**	**329**	**14%**

VYVGART® (efgartigimod alfa-fcab) Injection for Intravenous Use 400 mg/20 mL vial

VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Subcutaneous Injection 180 mg/mL and 2000 U/mL vial

Growth %'s are calculated using CER (Constant Exchange Rates)

argenx

2023 Financial Summary

Summary P/L

(in millions of $)	Three months ended December 31		Twelve months ended December 31	
	2023	2022	2023	2022
Product net sales	374	173	1,191	401
Other & collaboration revenue	43	9	78	45
Total operating income	418	182	1,269	445
Total operating expenses	(556)	(297)	(1,694)	(1,166)
Operating loss for the period	(139)	(114)	(425)	(720)
Financial income / (expense)	78	73	121	(9)
Loss before tax	(61)	(41)	(304)	(729)
Tax	(38)	3	9	20
Loss for the period	(99)	(39)	(295)	(710)

Total Operating Expenses include Cost of Sales, R&D, SG&A and Loss from investment in joint venture. Financial income / (expenses) includes financial income / (expenses) and exchange gains / (losses). Table in $'m and impacted by rounding.

Cash

Ended fourth quarter 2023
with cash of $3.2B

Cash reflects cash, cash equivalents and current financial assets

2024 Financial Guidance

($B)	2024
Cash burn(1)	~ 0.5
Combined R&D and SG&A expenses	< 2.0

(1) - Cash burn is equal to the decrease in our cash, cash equivalents and current financial assets

On Track To Be Sustainable

argenx


Continuing to drive transformational outcomes for patients
Reaching new gMG patients with VYVGART
Leveraging MG know-how into future indications
Maximizing value creation and patient im
Alexis, VYVGART Patient

Strong Commercial Execution in 2023

GROWTH

$1.2B
Global Product Revenue

21% 2023 CAGR

EARLIER LINE PATIENTS

>6,000*
Global VYVGART Patients

55% patients from orals

PRESCRIBER EXPANSION

>2,300*
Prescribers in the US

25% YoY increase

BROAD PATIENT ACCESS

~90%
Access VYVGART after ≤2 Orals

Favorable payor policies

BOLSTERED BY REAL-WORLD EXPERIENCE

- MSE 45%
- QoL
- Steroid tapering
- 4,000 patient years of safety follow-up

My VYVGART® Path

* As of Q3 2023 Financial Results

argenx

Innovation Builds Autoimmune Market Opportunities



Growing VYVGART shar

- US: VYVGART Hytrulo J-Code
- PFS development
- Added to China NRDL

Expanding VYVGART TA

- Seronegative trial
- Phase 3b studies and externally sponsored research
- Geographic expansion

Growing MG market

Targeted biologics are expanding gMG market by providing patients more treatment options

We Aim to Address the Unseen Suffering in CIDP



≤20% of patients achieve remission on current SOC (CDAS=2)*

>50% of patients are dissatisfied with their symptom burden**

>42K treated CIDP patients in US & ROW argenx markets (ex-China)***

* Gorson KC, et al. 2010
** Mendoza M, et al. 2023
*** argenx market research


Maximizing patient impact through our commercial organization
Generating Disease Awareness
Elevating Expectations for Treatment
Driving Innovation on Patient Experience
Providing Broad and Simple Access
Long-term commitment to repeatable, sustainable and comprehensive value creation
Caitlin, MG patient

We are on a bold mission

argenx

Exhibit 99.3

ARGENX SE

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

	As of December 31,		
(in thousands of $)	**2023**	**2022**	**2021**
ASSETS			
Non-current assets			
Property, plant and equipment	$ 22,675	$ 16,234	$ 15,844
Intangible assets	125,228	174,901	171,684
Deferred tax asset	97,211	79,222	32,191
Research and development incentive receivables	76,706	47,488	32,707
Investment in joint venture	9,912	1,323	—
Prepaid expenses	47,327	—	—
Other non-current assets	39,662	40,894	54,876
Total non-current assets	**418,721**	**360,064**	**307,303**
Current assets			
Inventories	$ 310,550	$ 228,353	$ 109,076
Prepaid expenses	134,072	76,022	58,946
Trade and other receivables	496,687	275,697	38,221
Research and development incentive receivables	2,584	1,578	—
Financial assets	1,131,000	1,391,808	1,002,052
Cash and cash equivalents	2,048,844	800,740	1,334,676
Total current assets	**4,123,737**	**2,774,197**	**2,542,971**
TOTAL ASSETS	**$ 4,542,458**	**$ 3,134,261**	**$ 2,850,274**

	As of December 31,		
(in thousands of $)	**2023**	**2022**	**2021**
EQUITY AND LIABILITIES			
Equity			
Equity attributable to owners of the parent			
Share capital	$ 7,058	$ 6,640	$ 6,233
Share premium	5,651,497	4,309,880	3,462,775
Translation differences	131,543	129,280	131,684
Accumulated losses	(2,404,844)	(2,109,791)	(1,400,197)
Other reserves	712,253	477,691	333,729
Total equity	**$ 4,097,507**	**$ 2,813,699**	**$ 2,534,224**
Non-current liabilities			
Provisions for employee benefits	1,449	870	417
Lease liabilities	15,354	9,009	7,956
Deferred tax liabilities	5,155	8,406	6,438
Total non-current liabilities	**21,958**	**18,285**	**14,811**
Current liabilities			
Lease liabilities	4,646	3,417	3,509
Trade and other payables	414,013	295,679	293,415
Tax liabilities	4,334	3,181	4,315
Total current liabilities	**422,993**	**302,277**	**301,239**
Total liabilities	**$ 444,951**	**$ 320,562**	**$ 316,050**
TOTAL EQUITY AND LIABILITIES	**$ 4,542,458**	**$ 3,134,261**	**$ 2,850,274**

ARGENX SE

CONSOLIDATED STATEMENTS OF PROFIT OR LOSS

	Year Ended December 31,		
(in thousands of $ except for shares and EPS)	**2023**	**2022**	**2021**
Product net sales	$ 1,190,783	$ 400,720	$ —
Collaboration revenue	35,533	10,026	497,277
Other operating income	42,278	34,520	42,141
Total operating income	**1,268,594**	**445,267**	**539,418**
Cost of sales	(117,835)	(29,431)	—
Research and development expenses	(859,492)	(663,366)	(580,520)
Selling, general and administrative expenses	(711,905)	(472,132)	(307,644)
Loss from investment in joint venture	(4,411)	(677)	—
Total operating expenses	**(1,693,643)**	**(1,165,607)**	**(888,164)**
Operating loss	**$ (425,049)**	**$ (720,341)**	**$ (348,746)**
Financial income	107,386	27,665	3,633
Financial expense	(906)	(3,906)	(4,578)
Exchange gains/(losses)	14,073	(32,732)	(50,053)
Loss for the year before taxes	**$ (304,496)**	**$ (729,314)**	**$ (399,743)**
Income tax benefit / (expense)	$ 9,443	$ 19,720	$ (8,522)
Loss for the year	**$ (295,053)**	**$ (709,594)**	**$ (408,265)**
Loss for the year attributable to:			
Owners of the parent	(295,053)	$ (709,594)	$ (408,265)
Weighted average number of shares outstanding	57,169,253	54,381,371	51,075,827
Basic and diluted (loss) per share (in $)	(5.16)	(13.05)	(7.99)

ARGENX SE

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

	Year Ended December 31,		
(in thousands of $)	**2023**	**2022**	**2021**
Loss for the year	**$ (295,053)**	**$ (709,594)**	**$ (408,265)**
Items that may be reclassified subsequently to profit or loss, net of tax			
Currency translation differences, arisen from translating foreign activities	2,263	(2,404)	(3,048)
Items that will not be reclassified subsequently to profit or loss, net of tax			
Fair value gain/(loss) on investments in equity instruments designated as at FVTOCI	(1,915)	(18,267)	(39,290)
Other comprehensive loss, net of income	**348**	**(20,671)**	**(42,338)**
Total comprehensive loss attributable to:			
Owners of the parent	**$ (294,705)**	**$ (730,266)**	**$ (450,603)**

ARGENX SE

CONSOLIDATED STATEMENTS OF CASH FLOWS

	Year Ended December 31,		
(in thousands of $)	**2023**	**2022**	**2021**
Operating loss	**$ (425,049)**	**$ (720,341)**	**$ (348,746)**
Adjustments for non-cash items			
Amortization of intangible assets	105,674	99,766	776
Depreciation of property, plant and equipment	5,633	4,576	5,091
Provisions for employee benefits	573	459	260
Expense recognized in respect of share-based payments	232,974	157,026	179,366
Fair value gains on financial assets at fair value through profit or loss	—	(4,256)	(11,152)
Non-cash revenue	—	—	(75,000)
Loss from investment in joint venture	4,411	677	—
Other non-cash expenses	2,074	—	—
	$ (73,710)	**$ (462,093)**	**$ (249,405)**
Movements in current assets/liabilities			
(Increase)/decrease in trade and other receivables	(185,694)	(222,260)	(31,632)
(Increase)/decrease in inventories	(83,030)	(119,277)	(83,880)
(Increase)/decrease in other current assets	(59,024)	(18,294)	(30,990)
Increase/(decrease) in trade and other payables	95,600	329	134,892
Increase/(decrease) in deferred revenue — current	—	—	(46,327)
Movements in non-current assets/liabilities			
(Increase)/decrease in other non-current assets	(29,416)	(16,220)	(13,975)
(Increase)/decrease in non-current prepaid expense	(47,327)	—	—
Increase/(decrease) in deferred revenue — non-current	—	—	(269,039)
Net cash flows used in operating activities	**(382,601)**	**(837,815)**	**(590,356)**
Interest paid	(211)	(851)	(684)
Income taxes paid	(37,515)	(24,141)	(15,772)
Net cash flows used in operating activities	**$ (420,327)**	**$ (862,807)**	**$ (606,812)**
Purchase of intangible assets	(43,000)	(102,986)	(117,811)
Purchase of property, plant and equipment	(812)	(837)	(3,623)
(Increase)/decrease in current financial assets	—	—	(228,239)
Purchase of current financial investments	(1,271,730)	(1,694,046)	—
Sale of current financial investments	1,543,999	1,325,540	—
Interest received	92,753	13,146	2,603
Investment in joint venture	(13,000)	(2,000)	—
Net cash flows (used in) / from investing activities	**$ 308,210**	**$ (461,184)**	**$ (347,070)**
Principal elements of lease payments	(3,801)	(4,165)	(3,855)
Proceeds from issue of new shares, gross amount	1,196,731	760,953	1,091,326
Issue costs paid	(821)	(781)	(528)
Exchange gain/(losses) from currency conversion on proceeds from issue of new shares	(1,507)	410	966
Payment of employee withholding taxes relating to restricted stock unit awards	(12,138)	(5,855)	—
Proceeds from exercise of stock options	158,263	93,195	33,433
Net cash flows from financing activities	**$ 1,336,727**	**$ 843,757**	**$ 1,121,342**
Increase/decrease (-) in cash and cash equivalents	**$ 1,224,610**	**$ (480,234)**	**$ 167,460**
Cash and cash equivalents at the beginning of the period	**$ 800,740**	**$ 1,334,676**	**$ 1,216,803**
Exchange gains/(losses) on cash and cash equivalents	$ 23,494	$ (53,702)	$ (49,587)
Cash and cash equivalents at the end of the period	**$ 2,048,844**	**$ 800,740**	**$ 1,334,676**

ARGENX SE

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

	Attributable to owners of the parent							
(in thousands of $)	**Share capital**	**Share premium**	**Accumulated losses**	**Translation differences**	**Share-based payment and income tax deduction on share-based payments**	**Fair value movement on investment in equity instruments designated as at FVTOCI**	**Total equity attributable to owners of the parent**	**Total equity**
Balance at January 1, 2021	**$ 5,744**	**$ 2,339,033**	**$ (991,932)**	**$ 134,732**	**$ 186,474**	**$ —**	**$ 1,674,051**	**$ 1,674,051**
Loss for the year			(408,265)				(408,265)	**(408,265)**
Other comprehensive income / (loss)				(3,048)		(39,290)	(42,338)	**(42,338)**
Total comprehensive income / (loss) for the year			**(408,265)**	**(3,048)**		**(39,290)**	**(450,603)**	**(450,603)**
Income tax benefit from excess tax deductions related to share-based payments					7,179		7,179	**7,179**
Share-based payment					179,366		179,366	**179,366**
Issue of share capital	430	1,090,896					1,091,326	**1,091,326**
Transaction costs for equity issue		(528)					(528)	**(528)**
Exercise of stock options	59	33,374					33,433	**33,433**
Balance year ended December 31, 2021	**$ 6,233**	**$ 3,462,775**	**$ (1,400,197)**	**$ 131,684**	**$ 373,019**	**$ (39,290)**	**$ 2,534,224**	**$ 2,534,224**
Loss for the year			(709,594)				(709,594)	**(709,594)**
Other comprehensive income / (loss)				(2,404)		(18,267)	(20,671)	**(20,671)**
Total comprehensive income / (loss) for the year			**(709,594)**	**(2,404)**		**(18,267)**	**(730,266)**	**(730,266)**
Income tax benefit from excess tax deductions related to share-based payments					3,946		3,946	**3,946**
Share-based payment					158,282		158,282	**158,282**
Issue of share capital	294	760,659					760,953	**760,953**
Transaction costs for equity issue		(781)					(781)	**(781)**
Exercise of stock options	113	93,082					93,195	**93,195**
Ordinary shares withheld for payment of employees' withholding tax liability		(5,855)					(5,855)	**(5,855)**
Balance year ended December 31, 2022	6,640	**4,309,880**	**(2,109,791)**	**129,280**	**535,247**	**(57,557)**	**2,813,699**	**2,813,699**
Loss for the year			(295,053)				(295,053)	**(295,053)**
Other comprehensive income / (loss)				2,263		(1,915)	348	**348**
Total comprehensive income / (loss) for the year			**(295,053)**	**2,263**		**(1,915)**	**(294,705)**	**(294,705)**
Income tax benefit from excess tax deductions related to share-based payments					2,310		2,310	**2,310**
Share-based payment					234,168		234,168	**234,168**
Issue of share capital	288	1,196,444					1,196,732	**1,196,732**
Transaction costs for equity issue		(821)					(821)	**(821)**
Exercise of stock options	130	158,133					158,263	**158,263**
Ordinary shares withheld for payment of employees' withholding tax liability		(12,139)					(12,139)	**(12,139)**
Balance year ended December 31, 2023	**$ 7,058**	**$ 5,651,497**	**$ (2,404,844)**	**$ 131,543**	**$ 771,725**	**$ (59,472)**	**$ 4,097,507**	**$ 4,097,507**